|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chi Z, Li S, Sheng X, Si L, Cui C, Han M
and Guo J: Clinical presentation, histology, and prognoses of
malignant melanoma in ethnic Chinese: A study of 522 consecutive
cases. BMC cancer. 11:852011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Network, . Genomic
classification of cutaneous melanoma. Cell. 161:1681–1696. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Flaherty KT, Puzanov I, Kim KB, Ribas A,
McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K and
Chapman PB: Inhibition of mutated, activated BRAF in metastatic
melanoma. N Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sosman JA, Kim KB, Schuchter L, Gonzalez
R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ,
Flaherty KT, et al: Survival in BRAF V600-mutant advanced melanoma
treated with vemurafenib. N Engl J Med. 366:707–714. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Coit DG, Thompson JA, Algazi A, Andtbacka
R, Bichakjian CK, Carson WE III, Daniels GA, DiMaio D, Fields RC,
Fleming MD, et al: NCCN guidelines insights: Melanoma, version
3.2016. J Natl Compr Canc Netw. 14:945–958. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Si L, Kong Y, Xu X, Flaherty KT, Sheng X,
Cui C, Chi Z, Li S, Mao L and Guo J: Prevalence of BRAF V600E
mutation in Chinese melanoma patients: Large scale analysis of BRAF
and NRAS mutations in a 432-case cohort. Eur J Cancer. 48:94–100.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Molina-Vila MA, de-Las-Casas CM,
Bertran-Alamillo J, Jordana-Ariza N, González-Cao M and Rosell R:
cfDNA analysis from blood in melanoma. Ann Transl Med.
3:3092015.PubMed/NCBI
|
|
10
|
Crowley E, Di Nicolantonio F, Loupakis F
and Bardelli A: Liquid biopsy: Monitoring cancer-genetics in the
blood. Nat Rev Clin Oncol. 10:472–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gonzalez-Cao M, Mayo-de-Las-Casas C,
Molina-Vila MA, De Mattos-Arruda L, Muñoz-Couselo E, Manzano JL,
Cortes J, Berros JP, Drozdowskyj A, Sanmamed M, et al: BRAF
mutation analysis in circulating free tumor DNA of melanoma
patients treated with BRAF inhibitors. Melanoma Res. 25:486–495.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Santiago-Walker A, Gagnon R, Mazumdar J,
Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild
A, Hwu P, et al: Correlation of BRAF mutation status in
circulating-free DNA and tumor and association with clinical
outcome across four BRAFi and MEKi clinical trials. Clin Cancer
Res. 22:567–574. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gray ES, Rizos H, Reid AL, Boyd SC,
Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, et al:
Circulating tumor DNA to monitor treatment response and detect
acquired resistance in patients with metastatic melanoma.
Oncotarget. 6:42008–42018. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reid AL, Freeman JB, Millward M, Ziman M
and Gray ES: Detection of BRAF-V600E and V600K in melanoma
circulating tumour cells by droplet digital PCR. Clin Biochem.
48:999–1002. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A,
Harada K, Shimada S, Saida T, Ferrone S, Takata M, Uhara H and
Okuyama R: Mutation analysis of BRAF and KIT in circulating
melanoma cells at the single cell level. Br J Cancer. 106:939–946.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kidess-Sigal E, Liu HE, Triboulet MM, Che
J, Ramani VC, Visser BC, Poultsides GA, Longacre TA, Marziali A,
Vysotskaia V, et al: Enumeration and targeted analysis of KRAS,
BRAF and PIK3CA mutations in CTCs captured by a label-free
platform: Comparison to ctDNA and tissue in metastatic colorectal
cancer. Oncotarget. 7:85349–85364. 2016.PubMed/NCBI
|
|
17
|
Jennings LJ, George D, Czech J, Yu M and
Joseph L: Detection and quantification of BCR-ABL1 fusion
transcripts by droplet digital PCR. J Mol Diagn. 16:174–179. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lawrence MS, Stojanov P, Polak P, Kryukov
GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH,
Roberts SA, et al: Mutational heterogeneity in cancer and the
search for new cancer-associated genes. Nature. 499:214–218. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Knol AC, Vallée A, Herbreteau G, Nguyen
JM, Varey E, Gaultier A, Théoleyre S, Saint-Jean M, Peuvrel L,
Brocard A, et al: Clinical significance of BRAF mutation status in
circulating tumor DNA of metastatic melanoma patients at baseline.
Exp Dermatol. 25:783–788. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsao SC, Weiss J, Hudson C, Christophi C,
Cebon J, Behren A and Dobrovic A: Monitoring response to therapy in
melanoma by quantifying circulating tumour DNA with droplet digital
PCR for BRAF and NRAS mutations. Sci Rep. 5:111982015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang GA, Tadepalli JS, Shao Y, Zhang Y,
Weiss S, Robinson E, Spittle C, Furtado M, Shelton DN,
Karlin-Neumann G, et al: Sensitivity of plasma BRAFmutant and
NRASmutant cell-free DNA assays to detect metastatic melanoma in
patients with low RECIST scores and non-RECIST disease progression.
Mol Oncol. 10:157–165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dawson SJ, Tsui DW, Murtaza M, Biggs H,
Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B,
et al: Analysis of circulating tumor DNA to monitor metastatic
breast cancer. N Engl J Med. 368:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Beaver JA, Jelovac D, Balukrishna S,
Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J,
Blair BG, et al: Detection of cancer DNA in plasma of patients with
early-stage breast cancer. Clin Cancer Res. 20:2643–2650. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sanmamed MF, Fernández-Landázuri S,
Rodríguez C, Zárate R, Lozano MD, Zubiri L, Perez-Gracia JL,
Martín-Algarra S and González A: Quantitative cell-free circulating
BRAFV600E mutation analysis by use of droplet digital PCR in the
follow-up of patients with melanoma being treated with BRAF
inhibitors. Clin Chem. 61:297–304. 2015. View Article : Google Scholar : PubMed/NCBI
|
